These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28436941)

  • 21. Prediction value of intercellular adhesion molecule-1 gene polymorphisms for epithelial ovarian cancer risk, clinical features, and prognosis.
    Cai G; Ma X; Zou W; Huang Y; Zhang J; Wang D; Chen B
    Gene; 2014 Aug; 546(1):117-23. PubMed ID: 23933413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
    Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
    Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy.
    Biason P; Visentin M; Talamini R; Stopar A; Giorda G; Lucia E; Campagnutta E; Toffoli G
    Pharmacogenomics; 2012 Nov; 13(14):1609-19. PubMed ID: 23148637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
    Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
    Liu WL; Zhao JZ; Wang ZZ; Dong B; Hou YY; Wu XX; Guo YJ
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jun; 52(6):403-410. PubMed ID: 28647964
    [No Abstract]   [Full Text] [Related]  

  • 29. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. nm23 gene polymorphisms are associated with survival of patients with epithelial ovarian cancer but not with susceptibility to disease.
    Li Y; Kang S; Qin JJ; Wang N; Zhou RM; Sun HY
    Gynecol Oncol; 2012 Sep; 126(3):455-9. PubMed ID: 22683585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women.
    Shi TY; Jiang Z; Jiang R; Yin S; Wang MY; Yu KD; Shao ZM; Sun MH; Zang R; Wei Q
    Tumour Biol; 2015 Sep; 36(9):6919-27. PubMed ID: 25854172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
    Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
    Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.
    Carron J; Brito AB; Torelli AC; Oliveira C; Derchain SF; Lima CS; Lourenço GJ
    Med Oncol; 2016 Oct; 33(10):112. PubMed ID: 27586145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
    Xie X; Yang M; Ding Y; Yu L; Chen J
    Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer.
    Zeng Y; Li TL; Zhang HB; Deng JL; Zhang R; Sun H; Wan ZR; Liu YZ; Zhu YS; Wang G
    Pharmacogenomics; 2019 Feb; 20(3):179-188. PubMed ID: 30672383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
    Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer.
    Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
    Gynecol Oncol; 2011 Sep; 122(3):554-9. PubMed ID: 21714991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.